Skip to main content
OpenTrials
Completed

NCT Number: NCT01677299

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

This study will evaluate how EFB0027 and EFB0026 behave in subjects with type 2 diabetes mellitus.

In addition, this study will compare the effects of EFB0027 and EFB0026 on circulating concentrations of glucose and gastrointestinal hormones in subjects with type 2 diabetes mellitus.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Celerion, Inc., Tempe, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is 19 to 70 (inclusive) years old at Visit 1 (Screening).
  • Is diagnosed with Type 2 Diabetes Mellitus with
  • HbA1c between 6.0 to 9.5% (inclusive) for subjects managing their diabetes with:

i. Diet and exercise alone, or ii. A stable regimen (minimum of 2 months at Visit 1) of metformin alone, or iii. A stable regimen (minimum of 2 months at Visit 1) of DPP-4 inhibitor alone, OR

  • HbA1c between 6.0 to 8.5% (inclusive) for subjects managing their diabetes with a stable (minimum of 2 months at Visit 1) combination regimen of metformin and DPP-4 inhibitors.
  • Has serum creatinine below the upper limit of normal at Visit 1 and an estimated creatinine clearance above 80 using the Crockroft and Gault equation (CrCl = [(140 - age) x body weight in kg] / (serum creatinine x 72) x (0.85 for females) [ref. 3].
  • Has a body mass index (BMI) of 25.0 to 40.0 kg/m^2 (inclusive) at Screening.
  • Is male, or is female and meets all of the following criteria:
  • Not breastfeeding
  • Negative pregnancy test result (human chorionic gonadotropin, beta subunit) at Visit 1 (Screening) (not applicable to hysterectomized females)
  • Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study
  • Has a physical examination with no clinically significant abnormalities as judged by the investigator.
  • Ability to understand and willingness to adhere to protocol requirements.
  • If on chronic thyroid pharmacologic therapy, the dose must be stable for at least 3 months prior to Visit 1 (Screening), and must have thyroid-stimulating hormone (TSH) test result in normal range at Visit 1 (Screening).

Exclusion criteria

  • Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:
  • Hepatic disease
  • Renal disease
  • Gastrointestinal disease
  • Endocrine disorder except diabetes
  • Cardiovascular disease
  • Seizure disorder
  • Organ transplantation
  • Chronic infection
  • Has any chronic disease requiring medication that has been adjusted in the past 90 days (subjects may take acute intermittent over-the-counter medications such as Tylenol, if needed).
  • Has any drug treatment that affects gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid within 2 days of Visit 1 (Screening).
  • Has had major surgery of any kind within 6 months of Visit 1 (Screening).
  • Has received a blood transfusion within 6 months of Visit 1 (Screening).
  • Has a history of >5 kg weight change within 3 months of Visit 1 (Screening).
  • Has clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities other than those expected in subjects with diabetes and judged by the investigator to be clinically significant at Visit 1 (Screening).
  • Has physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.
  • Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.
  • Has donated blood within 2 months of Visit 1 (Screening) or is planning to donate blood during the study.
  • Has used insulin within 3 months of Visit 1 (Screening).
  • Has received GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of Visit 1 (Screening).
  • Has known intolerance to metformin.
  • Has received any investigational drug within 1 month (or five half-lives of the investigational drug, whichever is greater) of Visit 1 (Screening).
  • Has known allergies or hypersensitivity to any component of study treatment.
  • Is employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company).
  • Smokes more than 10 cigarettes per day, 2 cigars per day, or uses more than 1 can of smokeless tobacco per week.

Treatment and study plan

EFB0027 (metformin delayed release)

Drug

Comparison of enteric-coating to assess effect on PK

Other names: Met DR

EFB0026 (metformin immediate-release)

Drug

Active comparator

Other names: Met IR, metformin, Glucophage

Primary outcomes

  1. Area Under the Curve (0-t) of Plasma Metformin

    Time frame: Time points at which data were collected to create the area under the curve (0-t) for plasma metformin were: t = -0.08, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 11 h relative to the start time of the standardized breakfast.

    Measures from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration. The dose of study medication was administered at t = -1 min relative to the start time of the standardized breakfast.

  2. Change in Fasting Plasma Glucose

    Time frame: Change from Baseline (Day 1) to Day 5

    LS mean difference from Baseline (Day 1) to Day 5

  3. Within Treatment Comparison Based on Ratios of AUCs of GLP-1

    Time frame: Ratio of Day 5 to Baseline

  4. Within Treatment Comparison Based on Ratios of AUCs of PYY

    Time frame: Ratio of Day 5 to Baseline

Sponsors and collaborators

Lead sponsor

Elcelyx Therapeutics, Inc.

Industry

Registry information

Official study title

A Randomized, Crossover Study Assessing the Effects of pH 6.5 Enteric Coating of Metformin HCl Tablets on Pharmacokinetics and Changes in Circulating Glucose and Gastrointestinal Hormone Concentrations in Subjects With Type 2 Diabetes Mellitus

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Sep 3, 2012
Registry last updated
Sep 20, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.